Literature DB >> 26887992

[Endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 71 patients and analysis of the prognostic factors].

Xicai Sun1, Juan Liu1, Huan Wang1, Huapeng Yu1, Jingjing Wang1, Houyong Li1, Yurong Gu1, Limin Guo1, Dehui Wang2.   

Abstract

OBJECTIVE: To evaluate the efficacy of endoscopic nasopharyngectomy in the management of recurrent nasopharyngeal cancers (NPC) and to identify the prognostic factors.
METHODS: Between January 2006 and March 2014, 71 patients who received endoscopic nasopharyngectomy for recurrent NPC were retrospectively reviewed. The sex and the age of the patients, T stage, and tumor necrosis were recorded. Correlation between clinicopathological features and survival time was analyzed. Kaplan-Meier analysis was used to calculate the disease overall survival, disease-specific survival, and disease-free survival rates. Cox multivariate regression analysis and ROC curve analysis were used to determine the predictive value of the parameters.
RESULTS: The median age of 71 patients with recurrent nasopharyngeal carcinoma was 51.0 years old. Male to female ratio was 2.9:1 (male: 53, female: 18). The lesions were staged as follows (AJCC, 2010, seventh edition): rT1, 27; rT2, 10; rT3, 19 and rT4, 15. All patients underwent successful endoscopic nasopharyngectomy. No patient was transferred to open approach. The mean operative time was 155 minutes. The average blood loss was 450 ml. Three patients needed intraoperative blood transfusion. No serious postoperative complications occurred. Postoperative follow-up time was 5-96 months. During follow-up, 48 cases survived, including that 7 patients survived with disease, 1 patient had pulmonary metastases, and 1 case had cervical lymph node metastasis. Two-year overall survival and disease-free survival rates were 74.0% and 60.5%, respectively. Five-year overall survival and disease-free survival rates were 39.0% and 31.9%, respectively. Multivariate analysis showed that tumor necrosis was an independent prognostic factor for survival in recurrent nasopharyngeal carcinoma patients (P=0.001).
CONCLUSION: Endoscopic nasopharyngectomy is a safe and effective procedure for the treatment of recurrent nasopharyngeal carcinoma.

Entities:  

Mesh:

Year:  2015        PMID: 26887992

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1673-0860


  5 in total

1.  A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma.

Authors:  Eugene Hung Chih Wong; Yew Toong Liew; Mohd Zulkiflee Abu Bakar; Elizabeth Yenn Lynn Lim; Narayanan Prepageran
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-12       Impact factor: 2.503

Review 2.  Recurrent Nasopharyngeal Cancer: Critical Review of Local Treatment Options Including Recommendations during the COVID-19 Pandemic.

Authors:  Michaela Svajdova; Marian Sicak; Pavol Dubinsky; Marek Slavik; Pavel Slampa; Tomas Kazda
Journal:  Cancers (Basel)       Date:  2020-11-25       Impact factor: 6.639

3.  Comparing the Effectiveness of Endoscopic Surgeries With Intensity-Modulated Radiotherapy for Recurrent rT3 and rT4 Nasopharyngeal Carcinoma: A Meta-Analysis.

Authors:  Zhouying Peng; Yumin Wang; Yaxuan Wang; Ruohao Fan; Kelei Gao; Hua Zhang; Weihong Jiang
Journal:  Front Oncol       Date:  2021-07-26       Impact factor: 6.244

Review 4.  Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge.

Authors:  Zhouying Peng; Yumin Wang; Ruohao Fan; Kelei Gao; Shumin Xie; Fengjun Wang; Junyi Zhang; Hua Zhang; Yuxiang He; Zhihai Xie; Weihong Jiang
Journal:  Cancers (Basel)       Date:  2022-08-25       Impact factor: 6.575

5.  The short-term outcomes for the early removal of pigtail catheter drainage within 24 hours of uniportal video-assisted anatomic surgery in patients with lung cancer.

Authors:  Shuo Zheng; Qinlang Shi; Qinya Ma; Qiang Fu; Kun Qiao
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.